 Shares of Apellis Pharmaceuticals Inc. APLS, 0.05 plunged 31.6 toward a 10-month low to pace all premarket losers Friday, after one of the Phase 3 studies of the biopharmaceutical companys eye disease treatment failed to meet its primary endpoint. The company said late Thursday that the OAKS study for pegcetacoplan met the primary endpoint, as it significantly reduced geographic atrophy GA lesion growth, while the DERBY study missed its primary endpoint of GA lesion growth reduction. 